Almagate (trade name Almax) is an aluminium- and magnesium-containing antacid. It was first described in 1984.[1][2]

Almagate
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaAl2Mg6(OH)14(CO3)2 · 4 H2O
Molar mass314.99 g/mol
3D model (JSmol)
  • [Al+3].[Mg+2].[Mg+2].[Mg+2].[OH-].[OH-].[OH-].[O-]C([O-])=O.[OH-].[OH-].[OH-].[OH-].O.O
  • InChI=1S/CH2O3.Al.3Mg.9H2O/c2-1(3)4;;;;;;;;;;;;;/h(H2,2,3,4);;;;;9*1H2/q;+3;3*+2;;;;;;;;;/p-9 checkY
  • Key:MTEOMEWVDVPTNN-UHFFFAOYSA-E checkY
  (verify)

Adverse effects

edit

Almagate is well tolerated. In a clinical trial, the most common adverse effects were diarrhea and nausea.[3]

References

edit
  1. ^ Moragues J, Beneyto JE, Fábregas JL, Spickett RG (1984). "Characterization of a new crystalline synthetic gastric antacid, almagate" (Free full text). Arzneimittel-Forschung. 34 (10A): 1346–9. PMID 6548918.
  2. ^ Beneyto JE, Fábregas JL, Moragues J, Spickett RG (1984). "Evaluation of a new antacid, almagate" (Free full text). Arzneimittel-Forschung. 34 (10A): 1350–4. PMID 6439224.
  3. ^ Suau A, Dominguez Martin A, Ferrando Cucarella J, Juncosa Iglesias L, Muñoz Benitez J, Nieto Calvet M, et al. (1984). "Treatment of gastric pyrosis with almagate in patients with and without endoscopically demonstrable duodenal ulcer. A multicentre clinical trial" (Free full text). Arzneimittel-Forschung. 34 (10A): 1380–3. PMID 6548926.